[
  {
    "ts": "2026-02-17T05:06:14+00:00",
    "headline": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
    "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "479ee86d-de25-3759-b84e-5c1e7bf2cf79",
      "content": {
        "id": "479ee86d-de25-3759-b84e-5c1e7bf2cf79",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
        "description": "",
        "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
        "pubDate": "2026-02-17T05:06:14Z",
        "displayTime": "2026-02-17T05:06:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T09:53:58+00:00",
    "headline": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
    "summary": "By Rishika Sadam and Kashish Tandon HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as",
    "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ef69071a-653c-3cf8-bb6f-68a439295705",
      "content": {
        "id": "ef69071a-653c-3cf8-bb6f-68a439295705",
        "contentType": "STORY",
        "title": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
        "description": "",
        "summary": "By Rishika Sadam and Kashish Tandon HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as",
        "pubDate": "2026-02-17T09:53:58Z",
        "displayTime": "2026-02-17T09:53:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307",
          "originalWidth": 800,
          "originalHeight": 555,
          "caption": "Visitors stand at the kiosk of Eli Lilly at the BioAsia conference in Hyderabad, India, February 17, 2026. Picture taken with a mobile phone. REUTERS/Sriparna Roy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LaVH8My_FiH8DJaTBmf_ww--~B/aD01NTU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307.cf.webp",
              "width": 800,
              "height": 555,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ETOYaUIPUkRQ0osUfmwUAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:59:15+00:00",
    "headline": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
    "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
    "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "21d56a56-9828-3df5-9adc-837d598cb836",
      "content": {
        "id": "21d56a56-9828-3df5-9adc-837d598cb836",
        "contentType": "STORY",
        "title": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
        "description": "",
        "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
        "pubDate": "2026-02-17T13:59:15Z",
        "displayTime": "2026-02-17T13:59:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:37:11+00:00",
    "headline": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
    "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
    "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "fc891e4e-058f-3c86-8eb0-9b7b6c8a2502",
      "content": {
        "id": "fc891e4e-058f-3c86-8eb0-9b7b6c8a2502",
        "contentType": "STORY",
        "title": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
        "description": "",
        "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
        "pubDate": "2026-02-17T13:37:11Z",
        "displayTime": "2026-02-17T13:37:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:00:00+00:00",
    "headline": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
    "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
    "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2cc10b68-13f5-3cd2-834a-dbbf47a32968",
      "content": {
        "id": "2cc10b68-13f5-3cd2-834a-dbbf47a32968",
        "contentType": "STORY",
        "title": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
        "description": "",
        "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
        "pubDate": "2026-02-17T13:00:00Z",
        "displayTime": "2026-02-17T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01",
          "originalWidth": 2937,
          "originalHeight": 807,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ifPBxklVPfQWRMt9MzCscw--~B/aD04MDc7dz0yOTM3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01.cf.webp",
              "width": 2937,
              "height": 807,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T_SRXnEVO.ZnOjhSkzL94Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]